Marker Therapeutics, Inc. (MRKR) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1248920,
    "name": "Marker Therapeutics, Inc.",
    "stock_name": "Marker Therapeutics, Inc.",
    "full_name": "Marker Therapeutics, Inc.",
    "name_url": "stocks-analysis/marker-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "1.42",
    "chg": 0.23,
    "chgp": "19.33%",
    "dir": 1,
    "prev_price": "1.19",
    "mcapval": "11.31",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US57055L2060",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "1.01 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/marker-therapeutics-inc-1248920-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Marker Therapeutics Experiences Revision in Its Stock Evaluation Amid Financial Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/marker-therapeutics-inc-financial-trend-shifts-from-negative-to-flat-despite-declining-sales-3718582",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/MarkerTherapeut_fintrenddot_3718582.png",
        "date": "2025-11-20 15:40:01",
        "description": "Marker Therapeutics, Inc. reported a challenging quarter ending June 2025, with significant declines in net sales and critical financial metrics. Despite achieving its highest operating cash flow, the company struggles with low net sales and negative returns, contrasting sharply with broader market performance."
      },
      {
        "title": "Is Marker Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-marker-therapeutics-inc-technically-bullish-or-bearish-3545708",
        "imagepath": "",
        "date": "2025-09-20 19:16:49",
        "description": "As of 11 September 2025, the technical trend for Marker Therapeutics, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with weak strength. Key indicators driving this stance include a bearish MACD on the weekly timeframe, bearish moving averages on the daily timeframe, and a bearish KST on both weekly and monthly timeframes. The RSI shows bullish momentum on the weekly but lacks a clear signal on the monthly. Additionally, the stock has significantly underperformed against the S&P 500 across multiple periods, with a year-to-date return of -69.13% compared to the S&P 500's 12.22%...."
      },
      {
        "title": "Is Marker Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-marker-therapeutics-inc-overvalued-or-undervalued-3542393",
        "imagepath": "",
        "date": "2025-09-20 17:51:44",
        "description": "As of 17 March 2022, the valuation grade for Marker Therapeutics, Inc. moved from does not qualify to risky. The company appears to be overvalued given its significant losses and negative returns across multiple periods. The Price to Book Value stands at 1.38, while the EV to Sales ratio is 1.11, indicating a premium relative to its sales despite the lack of profitability. Additionally, the ROE is a staggering -85.09%, reflecting severe inefficiencies in generating returns for shareholders.\n\nIn comparison to peers, Marker Therapeutics has a P/E ratio of -0.7992, while ImmunoPrecise Antibodies Ltd. shows a much higher P/E of -13.0409, and HOOKIPA Pharma, Inc. has a P/E of -0.1637, suggesting that Marker is struggling more than its counterparts. The company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -69.13% compared to the index's 12.22%, reinforcing the notion..."
      }
    ],
    "total": 8,
    "sid": "1248920",
    "stock_news_url": "https://www.marketsmojo.com/news/marker-therapeutics-inc-1248920"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Marker Therapeutics Experiences Revision in Its Stock Evaluation Amid Financial Challenges

2025-11-20 15:40:01

Marker Therapeutics, Inc. reported a challenging quarter ending June 2025, with significant declines in net sales and critical financial metrics. Despite achieving its highest operating cash flow, the company struggles with low net sales and negative returns, contrasting sharply with broader market performance.

Is Marker Therapeutics, Inc. technically bullish or bearish?

2025-09-20 19:16:49

As of 11 September 2025, the technical trend for Marker Therapeutics, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with weak strength. Key indicators driving this stance include a bearish MACD on the weekly timeframe, bearish moving averages on the daily timeframe, and a bearish KST on both weekly and monthly timeframes. The RSI shows bullish momentum on the weekly but lacks a clear signal on the monthly. Additionally, the stock has significantly underperformed against the S&P 500 across multiple periods, with a year-to-date return of -69.13% compared to the S&P 500's 12.22%....

Is Marker Therapeutics, Inc. overvalued or undervalued?

2025-09-20 17:51:44

As of 17 March 2022, the valuation grade for Marker Therapeutics, Inc. moved from does not qualify to risky. The company appears to be overvalued given its significant losses and negative returns across multiple periods. The Price to Book Value stands at 1.38, while the EV to Sales ratio is 1.11, indicating a premium relative to its sales despite the lack of profitability. Additionally, the ROE is a staggering -85.09%, reflecting severe inefficiencies in generating returns for shareholders. In comparison to peers, Marker Therapeutics has a P/E ratio of -0.7992, while ImmunoPrecise Antibodies Ltd. shows a much higher P/E of -13.0409, and HOOKIPA Pharma, Inc. has a P/E of -0.1637, suggesting that Marker is struggling more than its counterparts. The company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -69.13% compared to the index's 12.22%, reinforcing the notion...

View All News